Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Dee Executi if any		4. Transacti Code (Ins		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4	6. Date Exerc Expiration Da (Month/Day/Y		isable and ite	7. Title a Amount Securitie Underlyi Derivativ Security 3 and 4)	nd of es ng /e	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
		Tal					ies Acqu varrants,							d		
Common Stock 02/20/2						24 s 9,014 ⁽¹⁾		D	\$0.6	8(2) 20	55,025	D				
								Code	v	Amount	(A) or (D)	Price	Transa	ted action(s) 3 and 4)		(Instr. 4)
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day						Execution Date,		Transaction Disposed C Code (Instr. 5)		ies Acquired (A) o Of (D) (Instr. 3, 4				6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
(City)	(St		Zip) • I - No i	n-Deriva	s I	atisfy th	nis box to indic ne affirmative rities Acq	defense	conditi	ons of Rule 10	0b5-1(c). S	ee Instru	uction 10.		en plan that is int	ended to
					Rul	Rule 10b5-1(c) Transaction Indication										
(Street) SAN CA 94158 FRANCISCO												X Form filed by One Reporting Person Form filed by More than One Reportin Person				
455 MISSION BAY BLVD SOUTH					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Last) C/O NEI	`	First) (Middle) ERAPEUTICS			3. Date of Earliest Transaction (Month/Day/Year) 02/20/2024								X belov	v)	below D Officer	
1. Name and Address of Reporting Person [*] Zalevsky Jonathan					2. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS NKTR							heck all app Direc	licable)	10% (
		· *	,		2 199	uer Na	me and Tick	er or Tr	adina	Symbol		5	Relationshi	n of Reportir	ng Person(s) to	lesuer

Explanation of Responses:

1. Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.

(D)

(A)

2. This transaction was executed in multiple trades at prices ranging from \$0.66 to \$0.71. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

Date

Exercisable

Expiration

Date



** Signature of Reporting Person Date

Amount or Number

Shares

of

Title

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.